U.S. Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute)- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030
The U.S. Pain Management Drugs market size was valued at US$ 31.52 billion in 2021 and is expected to hit US$ 40.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.10% from 2022 to 2030.
- The study provides an in-depth analysis of the U.S. pain management drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
- Quantitative analysis from 2021 to 2030 is expected to enable the stakeholders to capitalize on prevailing U.S. pain management drugs market opportunities.
- The U.S. pain management drugs market size and estimations are based on a comprehensive analysis of key developments in the industry.
- Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.
Pain is an uncomfortable sensory and emotional sensation caused due to tissue injury or disease. It is caused due to injury and various diseases such as osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis, stomach ulcer, fibromyalgia and cancer. It can be defined as acute pain and chronic pain depending on duration.
This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak is anticipated to impact the growth of the pain management drugs market in the initial phase of the forecast period. The COVID-19 pandemic has stressed healthcare systems in the U.S., so that pain services in many clinics are no longer open for public services because of safety. Furthermore, the demand for pain management drugs is expected to rise during the latter half of the forecast period owing to telemedicine which has become an appropriate and effective way to offer necessary medical services to patients with chronic pain. Through telemedicine, physicians are able to provide guidance to patients for physical exercises at-home for pain relief.
Chronic pain is mainly caused due to aging conditions of bone and joints and nerve damage and injury. Pain is managed by a particular set of drugs to reduce the symptoms or treat pain. Pain process is complex and there are various drugs that provide relief by acting through a variety of physiological mechanism. Opioids are the most prescribed pain medication. These are narcotic pain medications containing natural and synthetic opiates. Opioids are usually used for acute pain, such as short-term pain after surgery. Morphine, Fentanyl, Oxycodone and Codeine are some of the opioids used for pain management.
As per the statistics by the National Cancer Institute, around 10.5 million individuals were reported to be suffering from cancer in the U.S. in 2021, and this number is expected to increase to 19.4 million in 2024. This is expected to increase the need of cancer pain drugs for therapeutic purposes, thus fueling the U.S. pain management drugs market growth.
In recent times there is increased use of pain management drugs due to rise in aging population. Increasing prevalence of diseases such as cancer, diabetic neuropathy, osteoarthritis and chronic arthritis, increasing number of surgical procedures and increasing healthcare expenditure are some of the key factors driving the growth for the U.S. pain management drugs market. In addition, increasing healthcare awareness is also fuelling the growth of U.S. pain management drugs market. However, increase in generic completion, patent expiration of blockbuster drugs and availability of substitutes such as pain relief devices are some of the major factors restraining the growth for U.S. pain management drugs market. In addition, prescribing drug abuse would inhibit the growth of the market.
Increasing R&D investment and outsourcing of pharmaceutical companies due to strong need for better treatment lead to market growth. In addition, novel molecule combination and drug delivery techniques would develop opportunity for the U.S. pain management drugs market. However, side effects of pain management drugs could lead a challenge for the pain management drugs market.
Report Scope of the U.S. Pain Management Drugs Market
Market Size in 2021
USD 31.52 Billion
Revenue Projection By 2030
USD 40.25 Billion
CAGR of 4.10% from 2022 to 2030
2017 - 2020
2022 to 2030
Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Boehringer Ingelheim, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc.
U.s. Pain Management Drugs Market Segmentation
The U.S. pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, it is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia, bone fracture, muscle sprain, acute appendicitis and other indications. On the basis of pain type, it is segmented into chronic pain and acute pain.
On the basis of drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.
By indication, the neuropathic pain segment accounted for a majority of the U.S. pain management drugs market share in 2021, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain segment are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries and rise in prevalence of chronic diseases that lead to back pain.
Some of the prominent players in the Pain Management Drugs market include:
- ABBOTT LABORATORIES
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- ELI LILY AND COMPANY
- GLAXOSMITHKLINE PLC (GSK)
- JOHNSON & JOHNSON
- MERCK & CO., INC.
- MYLAN N.V.
- NOVARTIS INTERNATIONAL AG
- PFIZER INC.
- PURDUE PHARMA L.P.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at U.S. for the period of 2017 to 2030
- BY DRUG CLASS
- Antimigraine drug
- Non-narcotic analgesics
- By Indication
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Back Pain
- Post-operative Pain
- Bone fracture
- Muscle sprain/strain
- Acute appendicitis
- By Pain Type
- Chronic pain
- Acute pain
Key Points Covered in U.S. Pain Management Drugs Market Study:
- Growth of U.S. Pain Management Drugs in 2022
- Market Estimates and Forecasts (2017-2030)
- Brand Share and Market Share Analysis
- Key Drivers and Restraints Shaping Market Growth
- Competition Mapping and Benchmarking
- Recommendation on Key Winning Strategies
- COVID-19 Impact on Demand for U.S. Pain Management Drugs and How to Navigate
- Key Product Innovations and Regulatory Climate
- U.S. Pain Management Drugs Consumption Analysis
- U.S. Pain Management Drugs Production Analysis
- U.S. Pain Management Drugs and Management